Aclarion Announces Inducement Grant to New Commercial Director, Western U.S.

Rhea-AI Summary

Aclarion (Nasdaq: ACON, ACONW) granted an inducement stock option to Daniel Keefe, its new Commercial Director, Western U.S., to purchase 17,000 shares on May 5, 2026. The option exercise price is $3.20 per share, equal to the closing price on the grant date.

One-fourth vests after one year; remaining options vest monthly over three years. The option term is ten years and was granted under Nasdaq Listing Rule 5635(c)(4) as an inducement material to Mr. Keefe joining the company.

News Market Reaction – ACON

+2.50%

+2.50% Session close to close

In the May 6 session, ACON gained 2.50%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement details an inducement stock option grant of 17,000 shares at $3.20 to the newly hi...

Analysis

This announcement details an inducement stock option grant of 17,000 shares at $3.20 to the newly hired Commercial Director for the Western U.S., reinforcing Aclarion’s recent commercial build-out following strong Q1 scan growth and triple-digit utilization. It follows board proposals to expand the 2022 Equity Incentive Plan, and comes after capital raises via registered direct offerings. Investors may watch how added commercial capacity translates into Nociscan adoption and future financial results.

Key Figures

Inducement options: 17,000 shares Exercise price: $3.20 per share Initial vesting: 25% after 1 year +2 more

5 metrics

Inducement options 17,000 shares Stock options granted to new Commercial Director, Western U.S.

Exercise price $3.20 per share Equal to Aclarion closing price on May 5, 2026 grant date

Initial vesting 25% after 1 year One-fourth of options vest on first anniversary of vesting commencement

Remaining vesting period 3 years Balance vests in equal monthly installments over next three years

Option term 10 years Duration of inducement stock option grant

Historical Context

5 past events · Latest: May 05 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
May 05	Commercial agreement	Positive	-3.3%	Second commercial agreement with Weill Cornell to expand Nociscan trial use.
Apr 30	Earnings update	Positive	+1.8%	Q1 2026 results with strong Nociscan scan growth and solid cash position.
Apr 28	Leadership hire	Positive	+0.0%	Appointment of Daniel Keefe as Commercial Director for Western U.S.
Apr 22	Buyback announcement	Positive	+10.8%	Announcement of a $2.5M stock repurchase plan funded with existing cash.
Apr 16	Patent grant	Positive	+3.8%	Issuance of U.S. patent for AI-driven analysis within Nociscan platform.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news on buybacks, patents, and strong Q1 metrics often coincided with positive price reactions, while some commercial and partnership updates saw flat or negative moves.

Recent Company History

Over the past few weeks, Aclarion announced a $2.5M stock repurchase plan and Q1 2026 results featuring 196% year-over-year scan volume growth and $19.0M in cash, which were followed by positive price moves. A new U.S. patent expanded its 64-asset IP portfolio, also aligning with gains. Conversely, a recent second commercial agreement with Weill Cornell Medicine and the earlier appointment of the same Commercial Director drew neutral to negative reactions, framing today’s inducement grant as part of a broader commercial build-out.

Key Terms

inducement stock option, exercise price, nasdaq listing rule 5635(c)(4), vesting

4 terms

inducement stock option financial

"granted Daniel Keefe ... an inducement stock option to purchase an aggregate of 17,000"

An inducement stock option is a grant of the right to buy company shares given to a new or existing employee as a special hiring or retention incentive, similar to offering a signing bonus but paid in future stock. Investors care because these options can motivate managers to grow the business and align their interests with shareholders, while also increasing the total number of shares over time and potentially diluting existing ownership and earnings per share.

exercise price financial

"The option has an exercise price of $3.20 per share, which was equal to the"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

nasdaq listing rule 5635(c)(4) regulatory

"The option was agreed to and granted in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

vesting financial

"One-fourth of the options vest on the one-year anniversary ... the remainder vest in equal"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Expansion of the commercial team reflects increasing demand for Nociscan, supported by triple-digit growth in utilization

BROOMFIELD, Colo., May 06, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms through its Nociscan® platform to help physicians identify the location of chronic low back pain and support improved treatment success rates, today announced that the compensation committee of Aclarion’s board of directors granted Daniel Keefe, the Company's recently-hired Commercial Director, Western U.S., an inducement stock option to purchase an aggregate of 17,000 shares of Aclarion's common stock on May 5, 2026. This stock option was agreed to as an inducement material to Mr. Keefe entering into employment with Aclarion. The option was agreed to and granted in accordance with Nasdaq Listing Rule 5635(c)(4).

The option has an exercise price of $3.20 per share, which was equal to the closing price of Aclarion's common stock on the grant date. One-fourth of the options vest on the one-year anniversary of the vesting commencement date, and the remainder vest in equal monthly installments over the next three years, subject to the new employee's continued service with the Company. The stock option has a 10-year term and is subject to the terms and conditions of an inducement stock option agreement covering the grant.

About Aclarion, Inc.

Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies. For more information, please visit www.aclarion.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about the Company’s current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as “anticipates,” “believes” and “expects” or similar expressions, are forward-looking statements. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the Company’s current plans and expectations, as well as future results of operations and financial condition. Forward-looking statements in this release include, among others, statements regarding the increasing demand for Nociscan. These and other risks and uncertainties are discussed more fully in our filings with the Securities and Exchange Commission. Readers are encouraged to review the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, as well as other disclosures contained in the Prospectus and subsequent filings made with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Contacts:

Kirin M. Smith
PCG Advisory, Inc.
ksmith@pcgadvisory.com

Media Contacts:

Jennie Kim
SPRIG Consulting
jennie@sprigconsulting.com

FAQ

What inducement grant did Aclarion (ACON) give Daniel Keefe on May 5, 2026?

Aclarion granted Daniel Keefe an inducement stock option to purchase 17,000 shares. According to Aclarion, the grant was made on May 5, 2026 as material inducement for his employment.

What is the exercise price and term of the ACON inducement option granted May 5, 2026?

The option exercise price is $3.20 per share and the term is 10 years. According to Aclarion, $3.20 equaled the closing price on the grant date and the option follows standard inducement agreement terms.

How does vesting work for the Aclarion (ACON) inducement stock option to Daniel Keefe?

One-fourth of the 17,000 options vests on the one-year anniversary of vesting commencement; the remainder vests monthly over three years. According to Aclarion, vesting is conditioned on continued service with the company.

Why was the option granted under Nasdaq Listing Rule 5635(c)(4) for Aclarion (ACON)?

The option was granted as an inducement material to hiring a new employee and therefore was issued under Nasdaq Listing Rule 5635(c)(4). According to Aclarion, the grant complies with that inducement-rule requirement.

Does the Aclarion inducement grant indicate changes to Nociscan commercial activity (ACON)?

The company links the hire to expanding commercial demand for Nociscan, citing triple-digit utilization growth. According to Aclarion, the commercial team expansion reflects increasing demand and prompted the inducement hire.